MCID: UTR032
MIFTS: 34

Uterine Body Mixed Cancer malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Body Mixed Cancer

Aliases & Descriptions for Uterine Body Mixed Cancer:

Name: Uterine Body Mixed Cancer 12 14
Malignant Mixed Tumor, Not Otherwise Specified 69
Malignant Mixed Tumor of Corpus Uteri 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4114
NCIt 47 C6311
UMLS 69 C1334628

Summaries for Uterine Body Mixed Cancer

Disease Ontology : 12 A uterine corpus cancer that has material basis in more than one type of cell.

MalaCards based summary : Uterine Body Mixed Cancer, also known as malignant mixed tumor, not otherwise specified, is related to uterine carcinosarcoma and mouth disease. An important gene associated with Uterine Body Mixed Cancer is PIK3R2 (Phosphoinositide-3-Kinase Regulatory Subunit 2), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Developmental Biology. The drugs Carboplatin and Ifosfamide have been mentioned in the context of this disorder. Related phenotypes are cardiovascular system and endocrine/exocrine gland

Related Diseases for Uterine Body Mixed Cancer

Diseases related to Uterine Body Mixed Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
id Related Disease Score Top Affiliating Genes
1 uterine carcinosarcoma 11.0
2 mouth disease 10.1 ERBB2 PGR
3 glioma 10.1 ERBB2 PGR
4 atypical lipomatous tumor 10.1 KIT PGR
5 mucoepidermoid thyroid carcinoma 10.1 ERBB2 PGR
6 marfanoid hypermobility syndrome 10.1 KIT PGR
7 triple-receptor negative breast cancer 10.1 ERBB2 PGR
8 skin angiosarcoma 10.1 KIT PGR
9 skin sarcoma 10.1 ERBB2 PGR
10 cervical lymphoepithelioma-like carcinoma 10.1 ERBB2 PGR
11 histiocytic and dendritic cell cancer 10.1 ERBB2 PGR
12 liver angiosarcoma 10.1 KIT PGR
13 uterine hypoplasia 10.1 KIT PGR
14 her2-receptor negative breast cancer 10.1 ERBB2 PGR
15 nervous system hibernoma 10.1 ERBB2 PGR
16 vulva basal cell carcinoma 10.1 KIT PGR
17 middle ear adenocarcinoma 10.1 KIT PGR
18 poliomyelitis 10.1 ERBB2 PGR
19 sebaceous adenoma 10.1 KIT PGR
20 basaloid squamous cell carcinoma 10.1 ERBB2 PGR
21 central nervous system mature teratoma 10.1 ERBB2 PGR
22 ovarian embryonal carcinoma 10.1 KIT PGR
23 extranodal nasal nk/t cell lymphoma 10.1 ERBB2 KIT
24 combined t cell and b cell immunodeficiency 10.1 ERBB2 PGR
25 mesenchymoma 10.1 KIT PGR
26 anomalous left coronary artery from the pulmonary artery 10.0 ERBB2 PGR
27 adult syndrome 10.0 PIK3CA PPP2R1A
28 male reproductive organ benign neoplasm 10.0 ERBB2 PGR
29 central nervous system primitive neuroectodermal neoplasm 10.0 ERBB2 PGR
30 pilar sheath acanthoma 10.0 KIT PGR
31 precursor t-lymphoblastic lymphoma/leukemia 10.0 KIT PIK3CA
32 kidney clear cell sarcoma 10.0 KIT PIK3CA
33 polyembryoma of the ovary 10.0 ERBB2 PGR
34 rectal neoplasm 10.0 ERBB2 KIT PGR
35 postpartum depression 10.0 ERBB2 KIT PGR
36 malignant pleural solitary fibrous tumor 10.0 ERBB2 KIT PGR
37 anus adenocarcinoma 10.0 ERBB2 PGR
38 proctitis 9.9 ERBB2 KIT PIK3CA
39 arthus reaction 9.9 ERBB2 KIT PGR PPP2R1A
40 nemaline myopathy 8, autosomal recessive 9.8 ERBB2 PIK3CA
41 fallopian tube carcinosarcoma 9.8 ERBB2 PGR
42 laryngeal neuroendocrine tumor 9.8 KIT PGR PIK3CA
43 infiltrating angiolipoma 9.8 ERBB2 PGR PIK3CA
44 progesterone-receptor negative breast cancer 9.8 ERBB2 PGR PIK3CA
45 dental caries 9.8 ERBB2 PGR PIK3CA
46 nasal cavity disease 9.8 ERBB2 PGR PIK3CA
47 trachea squamous cell carcinoma 9.8 ERBB2 PGR PIK3CA
48 reactive arthritis 9.7 ERBB2 KIT PGR PIK3CA
49 muscular dystrophy-dystroglycanopathy , type b, 2 9.7 ERBB2 KIT PGR PIK3CA
50 intestinal neuroendocrine benign tumor 8.8 CD109 ERBB2 KIT PGR PIK3CA PIK3R2

Graphical network of the top 20 diseases related to Uterine Body Mixed Cancer:



Diseases related to Uterine Body Mixed Cancer

Symptoms & Phenotypes for Uterine Body Mixed Cancer

MGI Mouse Phenotypes related to Uterine Body Mixed Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.85 ERBB2 KIT PGR PIK3CA PIK3R2 SOX7
2 endocrine/exocrine gland MP:0005379 9.8 CD109 ERBB2 KIT PGR PIK3CA SOX7
3 growth/size/body region MP:0005378 9.8 PPP2R1A SOX7 ERBB2 KIT PIK3CA PIK3R2
4 integument MP:0010771 9.63 CD109 ERBB2 KIT PGR PIK3CA PKP3
5 muscle MP:0005369 9.43 ERBB2 KIT PGR PIK3CA PIK3R2 SOX7
6 neoplasm MP:0002006 9.1 ERBB2 KIT PGR PIK3CA PIK3R2 PPP2R1A

Drugs & Therapeutics for Uterine Body Mixed Cancer

Drugs for Uterine Body Mixed Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
2
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
5
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
7
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 84093 441203 2767
8
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
9
Bleomycin Approved Phase 3 11056-06-7 5360373
10
Cortisone acetate Approved Phase 3 1950-04-4, 50-04-4 5745
11
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
12
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
13
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
14
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
15
Succinylcholine Approved Phase 3,Phase 1,Phase 2 306-40-1 5314
16
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
17
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
18 Sodium thiosulfate Approved Phase 3
19
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
20
Irinotecan Approved, Investigational Phase 3,Phase 2 97682-44-5, 100286-90-6 60838
21
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
22
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
23
Thiotepa Approved Phase 3,Phase 2 52-24-4 5453
24
Fluorouracil Approved Phase 3 51-21-8 3385
25
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
26
Ondansetron Approved Phase 3 99614-02-5 4595
27
Levoleucovorin Approved Phase 3 68538-85-2
28
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
29
Morphine Approved, Investigational Phase 3 57-27-2 5288826
30
Cyproheptadine Approved Phase 3 129-03-3 2913
31
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
33
leucovorin Approved, Nutraceutical Phase 3 58-05-9 54575, 6560146 143
34
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
35
Camptothecin Experimental Phase 3,Phase 2 7689-03-4
36 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2
37 Alkylating Agents Phase 3,Phase 2
38 Antimitotic Agents Phase 3,Phase 2,Phase 1
39 Antineoplastic Agents, Alkylating Phase 3,Phase 2
40 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
41 Isophosphamide mustard Phase 3,Phase 2
42 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
43 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
44 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
45 Antirheumatic Agents Phase 3,Phase 2
46 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
47 Liver Extracts Phase 3,Phase 2,Phase 1
48 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
49 Antiemetics Phase 3
50 Anti-Infective Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 72)
id Name Status NCT ID Phase
1 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
4 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3
5 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Completed NCT00352534 Phase 3
6 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3
7 Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Recruiting NCT00980460 Phase 3
8 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Active, not recruiting NCT01346267 Phase 3
9 Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System Active, not recruiting NCT00653068 Phase 3
10 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Active, not recruiting NCT00379340 Phase 3
11 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Active, not recruiting NCT00945009 Phase 3
12 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Active, not recruiting NCT00354835 Phase 3
13 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
14 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2
15 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2
16 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2
17 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2
18 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2
19 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2
20 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
21 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2
22 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2
23 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2
24 Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma Completed NCT00070304 Phase 2
25 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2
26 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
27 Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Completed NCT00047320 Phase 2
28 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Completed NCT01222715 Phase 2
29 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
30 Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer Completed NCT00019084 Phase 2
31 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2
32 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2
33 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2
34 Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT01281852 Phase 1, Phase 2
35 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2
36 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2
37 Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Recruiting NCT01935934 Phase 2
38 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2
39 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2
40 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Recruiting NCT02728258 Phase 2
41 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
42 Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT01935973 Phase 2
43 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
44 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2
45 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT00888173 Phase 2
46 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Active, not recruiting NCT01307631 Phase 2
47 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2
48 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Active, not recruiting NCT01154816 Phase 2
49 Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Active, not recruiting NCT02257528 Phase 2
50 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2

Search NIH Clinical Center for Uterine Body Mixed Cancer

Genetic Tests for Uterine Body Mixed Cancer

Anatomical Context for Uterine Body Mixed Cancer

Publications for Uterine Body Mixed Cancer

Variations for Uterine Body Mixed Cancer

Expression for Uterine Body Mixed Cancer

Search GEO for disease gene expression data for Uterine Body Mixed Cancer.

Pathways for Uterine Body Mixed Cancer

Pathways related to Uterine Body Mixed Cancer according to GeneCards Suite gene sharing:

(show all 37)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 ERBB2 KIT PIK3CA PIK3R2 PPP2R1A
2
Show member pathways
13.2 ERBB2 KIT PIK3CA PIK3R2 PKP3 PPP2R1A
3
Show member pathways
13.14 ERBB2 KIT PIK3CA PIK3R2 PPP2R1A
4
Show member pathways
12.81 ERBB2 KIT PIK3CA PIK3R2 PPP2R1A
5
Show member pathways
12.62 ERBB2 KIT PGR PIK3CA PIK3R2
6 12.42 ERBB2 KIT PIK3CA PIK3R2
7
Show member pathways
12.27 ERBB2 PIK3CA PIK3R2
8 12.27 KIT PIK3CA PIK3R2 PPP2R1A
9
Show member pathways
12.25 PIK3CA PIK3R2 PPP2R1A
10
Show member pathways
12.22 KIT PIK3CA PIK3R2
11
Show member pathways
12.14 ERBB2 PIK3CA PIK3R2
12
Show member pathways
12.12 ERBB2 PIK3CA PIK3R2
13 12.11 ERBB2 PIK3CA PIK3R2
14
Show member pathways
12.03 PIK3CA PIK3R2 PPP2R1A
15
Show member pathways
11.99 ERBB2 KIT PIK3CA PIK3R2 PPP2R1A
16
Show member pathways
11.98 KIT PIK3CA PIK3R2
17
Show member pathways
11.95 ERBB2 PIK3CA PIK3R2
18
Show member pathways
11.91 ERBB2 KIT PIK3CA PIK3R2
19
Show member pathways
11.9 ERBB2 PIK3CA PIK3R2
20 11.86 PIK3CA PIK3R2 PPP2R1A
21
Show member pathways
11.83 ERBB2 PIK3CA PIK3R2
22 11.8 PIK3CA PIK3R2 PPP2R1A
23
Show member pathways
11.8 PGR PIK3CA PIK3R2 PPP2R1A
24 11.77 ERBB2 PIK3CA PIK3R2
25
Show member pathways
11.7 ERBB2 PGR PIK3CA
26 11.63 ERBB2 PIK3CA PIK3R2
27
Show member pathways
11.5 KIT PIK3CA PIK3R2
28 11.36 ERBB2 PIK3CA PIK3R2
29 11.32 PIK3CA PIK3R2
30 11.27 PIK3CA PIK3R2
31 11.22 PIK3CA PIK3R2
32 11.14 ERBB2 PIK3CA
33 11.11 PIK3CA PIK3R2
34 10.98 PIK3CA PIK3R2
35 10.95 PIK3CA PIK3R2
36 10.84 PIK3CA PIK3R2
37 10.74 ERBB2 KIT PIK3CA PIK3R2

GO Terms for Uterine Body Mixed Cancer

Cellular components related to Uterine Body Mixed Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol 3-kinase complex GO:0005942 8.62 PIK3CA PIK3R2

Biological processes related to Uterine Body Mixed Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-mediated signaling GO:0048015 9.46 ERBB2 KIT PIK3CA PIK3R2
2 ERBB2 signaling pathway GO:0038128 9.32 ERBB2 PIK3CA
3 phosphatidylinositol 3-kinase signaling GO:0014065 9.26 ERBB2 PIK3R2
4 phosphatidylinositol phosphorylation GO:0046854 9.26 ERBB2 KIT PIK3CA PIK3R2
5 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 8.92 ERBB2 KIT PIK3CA PIK3R2

Molecular functions related to Uterine Body Mixed Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 1-phosphatidylinositol-3-kinase activity GO:0016303 9.16 PIK3CA PIK3R2
2 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.96 ERBB2 KIT
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.92 ERBB2 KIT PIK3CA PIK3R2

Sources for Uterine Body Mixed Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....